Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or Confirmed Gram-Positive Bacterial Pathogens

NCT00057369 is registered in ClinicalTrials.gov with Vicuron Pharmaceuticals as lead sponsor.

NCT NCT00057369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00057369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections With Suspected or Confirmed Gram-Positive Bacterial Pathogens
Lead sponsor
Vicuron Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2001
Completion date
June 30, 2003
Enrollment
88
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bacteremia